Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers !
Shipping Price Reduction for EU Regions
Kat. Nr. | Arten | Produktbeschreibung | Struktur | Reinheit | Merkmal |
---|---|---|---|---|---|
CO5-C82E3 | Cynomolgus | Biotinylated Cynomolgus Complement C5 Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
|
CO5-H5253 | Human | Human Complement C5 Protein, Fc Tag | ![]() |
![]() ![]() |
|
CO5-H82E9 | Human | Biotinylated Human Complement C5 Protein, His,Avitag™ | ![]() |
![]() ![]() |
|
CO5-R52H4 | Rabbit | Rabbit Complement C5 Protein, His Tag | ![]() |
![]() ![]() |
|
CO5-H52H7 | Human | Human Complement C5 (w917s) Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
|
CO5-H52Hx | Human | Human Complement C5 (R885H) Protein, His Tag | ![]() |
![]() ![]() |
|
CO5-C52Hx | Cynomolgus | Cynomolgus Complement C5 Protein, His Tag | ![]() |
![]() ![]() |
|
CO5-R52H5 | Rat | Rat Complement C5 Protein, His Tag | ![]() |
![]() ![]() |
|
CO5-M52H4 | Mouse | Mouse Complement C5 Protein, His Tag | ![]() |
![]() ![]() |
|
CO5-H52Ha | Human | Human Complement C5 Protein, His Tag (MALS verified) | ![]() |
![]() ![]() |
Immobilized Human Complement C5 Protein, Fc Tag (Cat. No. CO5-H5253) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Human C5a Human Antibody, Human IgG1 with a linear range of 0.5-4 ng/mL (QC tested).
The purity of Biotinylated Cynomolgus Complement C5 Protein, His,Avitag (Cat. No. CO5-C82E3) is more than 85% and the molecular weight of this protein is around 170-210 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Avacincaptad pegol | ARC-1905; ARC-187 | Approved | Archemix Corp | Zimura, Izervay | United States | Geographic Atrophy; Macular Degeneration | Astellas Pharma Inc, Iveric Bio Inc | 2023-08-04 | Polypoidal choroidal vasculopathy; Wet Macular Degeneration; Geographic Atrophy; Stargardt Disease; Macular Degeneration | Details |
Zilucoplan Sodium | RA-101495-SC; RA-101495 | Approved | Ra Pharmaceuticals Inc, Ucb Sa | ZILBRYSQ, Zilbrysq | Japan | Myasthenia Gravis | Ucb Japan Co Ltd | 2023-09-25 | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Muscular Diseases; Amyotrophic Lateral Sclerosis | Details |
Crovalimab | RO-711269; SKY-59; RG-6107; RO711269; CH-7092230; RO-7092230; RO-7112689; RO-7112689/F01 | Approved | Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd | 派圣凯, Piasky | Mainland China | Hemoglobinuria, Paroxysmal | Roche Pharma (Schweiz) Ag, Roche (China) Holding Ltd, Genentech Inc | 2024-02-06 | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome; Guillain-Barre Syndrome; Anemia, Sickle Cell | Details |
Ravulizumab | ALXN-1810; ALXN-1210 | Approved | Alexion Pharmaceuticals Inc, Xencor Inc | Ultomiris | United States | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2018-12-21 | Thrombotic Microangiopathies; Kidney Failure, Chronic; Acute Lung Injury; Amyotrophic Lateral Sclerosis; Renal Insufficiency, Chronic; Neuromyelitis Optica; Pneumonia, Viral; Acute Kidney Injury; Atypical Hemolytic Uremic Syndrome; Myasthenia Gravis; Lupus Nephritis; Respiratory Distress Syndrome, Adult; Coronavirus Disease 2019 (COVID-19); Heart Diseases; Kidney Diseases; Hemoglobinuria, Paroxysmal; Dermatomyositis; Glomerulonephritis, IGA | Details |
Eculizumab | LEX-98; h-5G1.1; 5G1-1; HAL-1 | Approved | Alexion Pharmaceuticals Inc | Soliris, 舒立瑞 | United States | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2007-03-16 | Anemia, Hemolytic, Autoimmune; Diabetes Mellitus; Macular Degeneration; Kidney Failure, Chronic; Guillain-Barre Syndrome; Thrombocytopenia; Urea Cycle Disorders, Inborn; Asthma; Nasopharyngeal Carcinoma; Neuromyelitis Optica; Glomerulonephritis, Membranoproliferative; Pre-Eclampsia; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Rejection of organ transplantation; Infant, Newborn, Diseases; Antiphospholipid Syndrome; Delayed Graft Function; Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal; Vagus Nerve Diseases; Rejection of renal transplantation; End Stage Liver Disease; Myasthenia Gravis; HELLP Syndrome | Details |
Pozelimab | REGN-3918 | Approved | VEOPOZ | United States | Protein-Losing Enteropathies | Regeneron Pharmaceuticals Inc | 2023-08-18 | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Protein-Losing Enteropathies | Details | |
Avacincaptad pegol | ARC-1905; ARC-187 | Approved | Archemix Corp | Zimura, Izervay | United States | Geographic Atrophy; Macular Degeneration | Astellas Pharma Inc, Iveric Bio Inc | 2023-08-04 | Polypoidal choroidal vasculopathy; Wet Macular Degeneration; Geographic Atrophy; Stargardt Disease; Macular Degeneration | Details |
Zilucoplan Sodium | RA-101495-SC; RA-101495 | Approved | Ra Pharmaceuticals Inc, Ucb Sa | ZILBRYSQ, Zilbrysq | Japan | Myasthenia Gravis | Ucb Japan Co Ltd | 2023-09-25 | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Coronavirus Disease 2019 (COVID-19); Muscular Diseases; Amyotrophic Lateral Sclerosis | Details |
Crovalimab | RO-711269; SKY-59; RG-6107; RO711269; CH-7092230; RO-7092230; RO-7112689; RO-7112689/F01 | Approved | Chugai Pharmaceutical Co Ltd, F. Hoffmann-La Roche Ltd | 派圣凯, Piasky | Mainland China | Hemoglobinuria, Paroxysmal | Roche Pharma (Schweiz) Ag, Roche (China) Holding Ltd, Genentech Inc | 2024-02-06 | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome; Guillain-Barre Syndrome; Anemia, Sickle Cell | Details |
Ravulizumab | ALXN-1810; ALXN-1210 | Approved | Alexion Pharmaceuticals Inc, Xencor Inc | Ultomiris | United States | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2018-12-21 | Thrombotic Microangiopathies; Kidney Failure, Chronic; Acute Lung Injury; Amyotrophic Lateral Sclerosis; Renal Insufficiency, Chronic; Neuromyelitis Optica; Pneumonia, Viral; Acute Kidney Injury; Atypical Hemolytic Uremic Syndrome; Myasthenia Gravis; Lupus Nephritis; Respiratory Distress Syndrome, Adult; Coronavirus Disease 2019 (COVID-19); Heart Diseases; Kidney Diseases; Hemoglobinuria, Paroxysmal; Dermatomyositis; Glomerulonephritis, IGA | Details |
Eculizumab | LEX-98; h-5G1.1; 5G1-1; HAL-1 | Approved | Alexion Pharmaceuticals Inc | Soliris, 舒立瑞 | United States | Hemoglobinuria, Paroxysmal | Alexion Pharmaceuticals Inc | 2007-03-16 | Anemia, Hemolytic, Autoimmune; Diabetes Mellitus; Macular Degeneration; Kidney Failure, Chronic; Guillain-Barre Syndrome; Thrombocytopenia; Urea Cycle Disorders, Inborn; Asthma; Nasopharyngeal Carcinoma; Neuromyelitis Optica; Glomerulonephritis, Membranoproliferative; Pre-Eclampsia; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Rejection of organ transplantation; Infant, Newborn, Diseases; Antiphospholipid Syndrome; Delayed Graft Function; Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal; Vagus Nerve Diseases; Rejection of renal transplantation; End Stage Liver Disease; Myasthenia Gravis; HELLP Syndrome | Details |
Pozelimab | REGN-3918 | Approved | VEOPOZ | United States | Protein-Losing Enteropathies | Regeneron Pharmaceuticals Inc | 2023-08-18 | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Protein-Losing Enteropathies | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Eculizumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Hemoglobinuria, Paroxysmal | Details | |
Eculizumab biosimilar (IBC GENERIUM) | Phase 3 Clinical | Ibc Generium | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details | |
Gefurulimab | TPP-2511; ALXN-1720; CON-9978 | Phase 3 Clinical | Alexion Pharmaceuticals Inc | Myasthenia Gravis; Proteinuria | Details |
Eculizumab biosimilar (Biocad) | BCD-148 | Phase 3 Clinical | Biocad | Hemoglobinuria, Paroxysmal | Details |
Cemdisiran | ALN-62643; ALN-CC5; AD-62643 | Phase 3 Clinical | Alnylam Pharmaceuticals Inc | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Atypical Hemolytic Uremic Syndrome | Details |
Eculizumab biosimilar (Amgen) | ABP-959 | Phase 3 Clinical | Amgen Inc | Hemoglobinuria, Paroxysmal | Details |
Nomacopan | EV-576; rEV-576; rVA576 | Phase 3 Clinical | Evolutec | Hemoglobinuria, Paroxysmal; Thrombotic Microangiopathies; Pemphigoid, Bullous; Geographic Atrophy; Keratoconjunctivitis | Details |
Eculizumab biosimilar (Samsung Bioepis) | SB-12; AM004; SB12 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Hemoglobinuria, Paroxysmal | Details |
Vensobafusp alfa | P014; KP-104 | Phase 2 Clinical | Kira Pharmaceuticals LLC | Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Kidney Diseases; Thrombotic Microangiopathies; Lupus Erythematosus, Systemic; Glomerulonephritis | Details |
Omoprubart | CAN-106 | Phase 2 Clinical | Beihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd | Hemoglobinuria, Paroxysmal; Genetic Diseases, Inborn | Details |
IM-101 | IM-101 | Phase 1 Clinical | ImmunAbs Inc | Autoimmune Diseases | Details |
ALXN-5500 | ALXN-5500 | Phase 1 Clinical | Alexion Pharmaceuticals Inc | Hemoglobinuria, Paroxysmal | Details |
RLYB-116 | RLYB-116 | Phase 1 Clinical | Rallybio Llc | Hematologic Diseases; Immune System Diseases; Inflammation | Details |
NM3086 | NM3086; NM-3086 | Phase 1 Clinical | NovelMed Therapeutics Inc | Hemoglobinuria, Paroxysmal | Details |
Eculizumab biosimilar (Turgut Ardika) | TUR03; TUR-03 | Phase 1 Clinical | Turgut Ardika Pty Ltd | Details | |
LP-005 | LP-005; RX-001 | Phase 1 Clinical | Longbio Pharma (Suzhou) Co Ltd | Peripheral Nervous System Diseases; Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Kidney Diseases; Amyotrophic Lateral Sclerosis | Details |
eculizumab biosimilar(Isu Abxis) | ISU-305 | Phase 1 Clinical | Isu Abxis Co Ltd | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details |
Eculizumab biosimilar (CinnaGen) | Phase 3 Clinical | Cinnagen | Hemoglobinuria, Paroxysmal | Details | |
Eculizumab biosimilar (IBC GENERIUM) | Phase 3 Clinical | Ibc Generium | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details | |
Gefurulimab | TPP-2511; ALXN-1720; CON-9978 | Phase 3 Clinical | Alexion Pharmaceuticals Inc | Myasthenia Gravis; Proteinuria | Details |
Eculizumab biosimilar (Biocad) | BCD-148 | Phase 3 Clinical | Biocad | Hemoglobinuria, Paroxysmal | Details |
Cemdisiran | ALN-62643; ALN-CC5; AD-62643 | Phase 3 Clinical | Alnylam Pharmaceuticals Inc | Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Atypical Hemolytic Uremic Syndrome | Details |
Eculizumab biosimilar (Amgen) | ABP-959 | Phase 3 Clinical | Amgen Inc | Hemoglobinuria, Paroxysmal | Details |
Nomacopan | EV-576; rEV-576; rVA576 | Phase 3 Clinical | Evolutec | Hemoglobinuria, Paroxysmal; Thrombotic Microangiopathies; Pemphigoid, Bullous; Geographic Atrophy; Keratoconjunctivitis | Details |
Eculizumab biosimilar (Samsung Bioepis) | SB-12; AM004; SB12 | Phase 3 Clinical | Samsung Bioepis Co Ltd | Hemoglobinuria, Paroxysmal | Details |
Vensobafusp alfa | P014; KP-104 | Phase 2 Clinical | Kira Pharmaceuticals LLC | Hemoglobinuria, Paroxysmal; Glomerulonephritis, IGA; Kidney Diseases; Thrombotic Microangiopathies; Lupus Erythematosus, Systemic; Glomerulonephritis | Details |
Omoprubart | CAN-106 | Phase 2 Clinical | Beihai Kangcheng (Beijing) Pharmaceutical Technology Co Ltd | Hemoglobinuria, Paroxysmal; Genetic Diseases, Inborn | Details |
IM-101 | IM-101 | Phase 1 Clinical | ImmunAbs Inc | Autoimmune Diseases | Details |
ALXN-5500 | ALXN-5500 | Phase 1 Clinical | Alexion Pharmaceuticals Inc | Hemoglobinuria, Paroxysmal | Details |
RLYB-116 | RLYB-116 | Phase 1 Clinical | Rallybio Llc | Hematologic Diseases; Immune System Diseases; Inflammation | Details |
NM3086 | NM3086; NM-3086 | Phase 1 Clinical | NovelMed Therapeutics Inc | Hemoglobinuria, Paroxysmal | Details |
Eculizumab biosimilar (Turgut Ardika) | TUR03; TUR-03 | Phase 1 Clinical | Turgut Ardika Pty Ltd | Details | |
LP-005 | LP-005; RX-001 | Phase 1 Clinical | Longbio Pharma (Suzhou) Co Ltd | Peripheral Nervous System Diseases; Myasthenia Gravis; Hemoglobinuria, Paroxysmal; Kidney Diseases; Amyotrophic Lateral Sclerosis | Details |
eculizumab biosimilar(Isu Abxis) | ISU-305 | Phase 1 Clinical | Isu Abxis Co Ltd | Hemoglobinuria, Paroxysmal; Atypical Hemolytic Uremic Syndrome | Details |
This web search service is supported by Google Inc.